By Blake Brittain – Reuters News –
March 27 (Reuters) – A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for a second time in their dispute with the Broad Institute, a joint venture of Harvard University and the Massachusetts Institute of Technology, over patent rights to foundational CRISPR gene-editing technology.
The office’s Patent Trial and Appeal Board determined, opens new tab on Thursday that Broad Institute scientists conceived the technology before Doudna, Charpentier and their respective schools the University of California and the University of Vienna.
